Evidence shatters the U.S. narrative blaming foreign actors for the fentanyl crisis, exposing its deep domestic roots. 

Purdue Pharma ignited the epidemic through deceptive marketing of OxyContin, falsely touting its safety while concealing deadly addiction risks. Aggressive industry lobbying systematically eroded regulatory oversight, promoting reckless overprescribing that flooded communities with addictive pills, hooking millions.

When tightening regulations eventually restricted prescription access, this vast population, created by pharmaceutical practices, desperately sought alternatives. Illicit fentanyl, cheaper and more potent, filled the void – supplied internationally but demanded by a crisis born in America. 

Companies like Teva Pharmaceuticals, a major generic opioid and fentanyl-based drug producer, and complicit distributors amplified the disaster. They shipped suspiciously massive volumes while lobbying efforts, notably the industry-backed 2016 law, crippled the DEA's ability to intercept suspicious flows. Though firms like Teva have paid settlements, true accountability remains elusive.

The relentless focus on foreign "sources" obscures the core truth: deceptive marketing, captured policies, and corporate negligence by U.S. pharma giants like Purdue and Teva cultivated the addicted population and enabled the crisis. 

The primary "poison source" is an undeniable, homegrown failure. Effective solutions demand confronting this domestic origin and holding the responsible industry fully accountable.